News

News & Reports 2018-03-22T10:04:39+00:00

Have some news you want to share with the Oregon Bio community?  Fill out our submission form.

Veana Therapeutics Announces Interim Results of the Phase I Trial for VIMO-001

Developing innovative immunotherapy products that effectively treat cancer patients and have minimal impact on their quality of life.

FOR IMMEDIATE PRESS RELEASE
April 5, 2018

Veana Therapeutics, Inc. is pleased to announce the interim results of the Phase I safety trial of its lead cancer immunotherapy drug asset, VIMO-001, in patients with advanced cancer. The Phase I clinical study is an “all comers” trial of patients with advanced and diverse cancer indications, including pancreatic, lung, prostate, renal, esophageal, […]

April 6th, 2018|

Portland biotech community finally gets its wish: a new lab-office project

Elizabeth Hayes, Portland Business Journal

Summit Development Group to invest $12M in Central Eastside lab-office development

One of the biggest obstacles for biotech companies looking to expand in Portland is the city’s lack of suitable lab space.

That situation is about to change. A new 40,000-square-foot lab-office development, scheduled to get underway in April, is slated to open in the fall in Portland’s Central Eastside.

Summit Development Group bought a 100-year-old, three-story warehouse building on the corner of Southeast […]

March 1st, 2018|

Legacy Health Foundation collects its largest grant for cancer research

Elizabeth Hayes, Portland Business Journal

The Wayne D. Kuni & Joan E. Kuni Foundation has awarded $5 million to Legacy Health Foundation to found a cancer research project.

The grant, the largest the Foundation has collected, will fund research into how cancer can be targeted by manipulating adenosine kinase, an enzyme that controls cell growth.

The research is led by Detlev Boison, Dow Chair of Neurology and director of neurobiology research and basic and translational research at Legacy […]

February 22nd, 2018|

Legislature 2018: Nosse’s new drug pricing bill is slimmed down but still controversial

By Elizabeth Hayes, Staff Reporter
Portland Business Journal

Rep. Rob Nosse, undeterred by the failure of his comprehensive prescription drug pricing bill last year, returned the House Health Care Committee on Monday to sell a new, slimmed down version.

House Bill 4005 would force more transparency on drug manufacturers, but it doesn’t specifically impose price controls. Nosse hopes that will make it an easier sell. The Portland Democrat has bipartisan support this time around.

“House Bill […]

February 8th, 2018|

‘Lifting all boats’: Kate Brown focuses on 2019 education plan in state of the state speech

SALEM — Gov. Kate Brown opened the 35-day legislative session Monday with a speech laying out her plan to improve technical education and training programs so more Oregonians can land jobs in growth industries such as bioscience and health care.

Much of the plan centers on a $300 million proposal she said she will bring to the […]

February 6th, 2018|

Medintellibase150shaded

Welcome to Overnight Health Care, sponsored by the Pharmaceutical Care Management Association. It's Wednesday in Washington, where lawmakers are already eyeing the long Memorial Day weekend and w [...]

Longtime Gilead research vet Norbert Bischofberger has landed at the cancer drug discovery startup Kronos Bio as its new president and CEO. He stepped down in April as executive VP for R&D and chi [...]

AstraZeneca has officially opened its new research facility in South San Francisco, bundling five of its Bay Area sites into a single unit at the heart of California's biotech cluster. [...]

A group of 127 House Democrats is calling on White House Office of Management and Budget (OMB) Director Mick Mulvaney to reject a proposal that would roll back ObamaCare's anti-discrimination pro [...]

Verrica Pharmaceuticals has filed to raise $86 million from public investors. The planned IPO will give Verrica the money it needs to take a treatment for viral skin infection molluscum through phase [...]

Gilde Healthcare and Versant Ventures have driven Lava Therapeutics to a €16 million ($18.8 million) financing. The round equips Lava to advance bispecific engagers of gamma-delta (γδ) T cells, a [...]

Welcome to Overnight Health Care, sponsored by the Pharmaceutical Care Management Association.  Today was a big day for proponents of the government expanding access to experimental medical treatments [...]

A joint venture of Vifor Pharma Group and Fresenius Medical Care acquired an international license to Cara Therapeutics' investigational Korsuva injection, an alternative opioid analgesic with a [...]